Current issue Clinical Oncology

315

320

Can a negative PSMA PET/CT limit the indication for lymphadenectomy in patients with localized moderate- and high-risk prostate cancer?

MUDr. Kristýna Dianová, doc. MUDr. Vladimír Šámal, Ph.D., MUDr. Vít Paldus

325

FLAURA2 – a step forward in first-line treatment of advanced EGFR-mutated non-small cell lung cancer

MUDr. Ján Podhorec, prof. MUDr. Alexandr Poprach, Ph.D.

331

Graft versus host disease as a marker for assessing quality of life in patients after allogeneic hematopoietic cell transplantation – results of a retrospective study

MUDr. Simona Pavúková, MUDr. Roman Králik, MUDr. Dana Dudová, prof. MUDr. Juraj Payer, PhD., MPH, FRCP, FEFIM1, doc. MUDr. Ľuboš Drgoňa, CSc., MHA, FECMM2

337

Prediction of residual disease after chemotherapy in advanced NSGCT – does microRNA provide clinical benefits?

MUDr. Tomáš Pokrivčák, Ph.D., doc. Mgr. Roman Hrstka, Ph.D., Mgr. Jan Švancara, doc. MUDr. Radek Lakomý, Ph.D., prof. MUDr. Alexandr Poprach, Ph.D., doc. MUDr. Michal Staník, Ph.D., MUDr. Iva Babánková, MUDr. Jan Křístek, Ph.D., prof. MUDr. Igor Kiss, Ph.D., MBA

344

With the exception of perinephritic fluid collection, all symptoms of TEMPI syndrome resolved following treatment for Waldenström macroglobulinemia

prof. MUDr. Zdeněk Adam, CSc., doc. MUDr. Jiří Vaníček, Ph.D., doc. MUDr. Zdeněk Řehák, Ph.D., MUDr. Sandra Soboličová, MUDr. Svatopluk Nehyba, Ph.D., MUDr. Lenka Kubková, Mgr. Jana Kotašková, Ph.D., Mgr. Marek Borský, MUDr. Marián Felšӧci, Ph.D., MUDr. Aleš Čermák, Ph.D., MUDr. Eva Šimarová, MUDr. Jakub Šlampa, MUDr. Lan Ngoc Leová, MUDr. Ivanna Boichuk, MUDr. Viera Sandecká, Ph.D., MUDr. Martin Štork, Ph.D., prof. MUDr. Marta Krejčí, Ph.D., prof. MUDr. Luděk Pour, Ph.D.

356

Ivosidenib in the treatment of IDH1-mutated cholangiocarcinoma – a review of current evidence and case report demonstrating durable disease control

MUDr. Michal Eid, Ph.D., MUDr. Udmila Eidová, Ph.D.

364

Long term response to immunotherapy in a patient with low PD-L1 expression, high tumor mutational burden, and STK11 mutation

MUDr. Michal Kysela, MUDr. Ondřej Bílek, Ph.D., doc. MUDr. Radka Lordick Obermannová, Ph.D., MUDr. Peter Grell, Ph.D.

368

Detection of RET fusion in late-line treatment of NSCLC followed by long-term disease control with selpercatinib

Miriam Šuranová, MUDr. Ondřej Bílek, Ph.D., MUDr. Aleš Neumann, Ph.D., Mgr. Jitka Berkovcová, Ph.D., doc. MUDr. Tomáš Kazda, Ph.D., prof. MUDr. Igor Kiss, Ph.D.

372

Pregnancy-associated EGFR-mutant lung adenocarcinoma in a TB-endemic region – diagnostic bias and therapeutic barriers

Dr. Muhammad Hafiz, SpP, Prof. Dr. Aziza G. Icksan, Dr. Ph. Sita Laksmi Andarini D, Ph.D, SpP, Dr. Nur M Karim, SpR, Dr. Annisa Dian Hari Hasari, SpP, Farhana Ibrahim Syuaib, MD, Dr. Retno Widyawati, SpPA, Dr. Tati Herdawati, SpPA

378

Diagnostic anchoring in metastatic adenocarcinoma – Was the turning point too late?

Dr. Muhammad Hafiz, Spp

381

Inhibice IDH u low-grade gliomů – horká současnost a zároveň racionální medicína

385

Léčba nádorů GIT v éře precizní medicíny

394

Aktuality z Národního ústavu pro výzkum rakoviny

Clinical Oncology - Issue 5/2026

Editorial

Review

Original Articles

Case Report

Letter to Editor

NUVR Reports

Clinical Oncology